Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study

Arlene E Garcia-Soto, James J. Java, Wilberto Nieves-Neira, Matt Pearson, David E. Cohn, Shashikant B. Lele, Krishnansu S. Tewari, Joan L. Walker, Angeles Alvarez Secord, Deborah K. Armstrong, Larry J. Copeland

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives To determine the relationship of the time from surgery to intraperitoneal (IP) chemotherapy (TSIC) initiation with survival of patients with stage III epithelial ovarian cancer (EOC) patients using ancillary data from cooperative group clinical trials. Methods Data from 420 patients with stage III EOC treated with IP chemotherapy under GOG-0114 and 172 were reviewed. The Cox proportional hazards model was used to evaluate independent prognostic factors and estimate their covariate-adjusted effects on PFS and OS. Results The median TSIC was 62.5 days (interquartile range 28–83). The median TSIC was longer for patients in GOG-0114 vs those in GOG-172 (83 vs 26 days, p < 0.001). TSIC was significantly associated (p = 0.049) with PFS: each 10% increase in TSIC (days) decreases the risk of progression by 3%. TSIC was not significantly associated with OS in this model. In a linear regression model, gross residual disease was significantly associated with shorter TSIC (R2 − 0.141, 95%CI − 0.217, − 0.064, p < 0.001). When only data from GOG-172 were considered, no statistical significant association was found between TSIC and PFS or OS. Conclusions In this ancillary data study, TSIC was not associated with improved OS in patients with stage III epithelial ovarian cancer. TSIC was significantly associated with PFS for the entire cohort, suggesting increase in PFS with longer TSIC. However, this was not found when only data from GOG 172 or GOG 114 were analyzed separately. Hence, the relationship between IP chemotherapy initiation and time from surgery needs to be studied further.

Original languageEnglish (US)
Pages (from-to)484-489
Number of pages6
JournalGynecologic Oncology
Volume143
Issue number3
DOIs
StatePublished - 2016

Fingerprint

Ovarian Neoplasms
Drug Therapy
Linear Models
Proportional Hazards Models
Clinical Trials
Survival
Ovarian epithelial cancer

Keywords

  • NRG Oncology
  • Ovarian cancer
  • Time interval between surgery and IP chemo

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. / Garcia-Soto, Arlene E; Java, James J.; Nieves-Neira, Wilberto; Pearson, Matt; Cohn, David E.; Lele, Shashikant B.; Tewari, Krishnansu S.; Walker, Joan L.; Alvarez Secord, Angeles; Armstrong, Deborah K.; Copeland, Larry J.

In: Gynecologic Oncology, Vol. 143, No. 3, 2016, p. 484-489.

Research output: Contribution to journalArticle

Garcia-Soto, Arlene E ; Java, James J. ; Nieves-Neira, Wilberto ; Pearson, Matt ; Cohn, David E. ; Lele, Shashikant B. ; Tewari, Krishnansu S. ; Walker, Joan L. ; Alvarez Secord, Angeles ; Armstrong, Deborah K. ; Copeland, Larry J. / Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. In: Gynecologic Oncology. 2016 ; Vol. 143, No. 3. pp. 484-489.
@article{6e48de236c9b43049d644733c565556b,
title = "Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study",
abstract = "Objectives To determine the relationship of the time from surgery to intraperitoneal (IP) chemotherapy (TSIC) initiation with survival of patients with stage III epithelial ovarian cancer (EOC) patients using ancillary data from cooperative group clinical trials. Methods Data from 420 patients with stage III EOC treated with IP chemotherapy under GOG-0114 and 172 were reviewed. The Cox proportional hazards model was used to evaluate independent prognostic factors and estimate their covariate-adjusted effects on PFS and OS. Results The median TSIC was 62.5 days (interquartile range 28–83). The median TSIC was longer for patients in GOG-0114 vs those in GOG-172 (83 vs 26 days, p < 0.001). TSIC was significantly associated (p = 0.049) with PFS: each 10{\%} increase in TSIC (days) decreases the risk of progression by 3{\%}. TSIC was not significantly associated with OS in this model. In a linear regression model, gross residual disease was significantly associated with shorter TSIC (R2 − 0.141, 95{\%}CI − 0.217, − 0.064, p < 0.001). When only data from GOG-172 were considered, no statistical significant association was found between TSIC and PFS or OS. Conclusions In this ancillary data study, TSIC was not associated with improved OS in patients with stage III epithelial ovarian cancer. TSIC was significantly associated with PFS for the entire cohort, suggesting increase in PFS with longer TSIC. However, this was not found when only data from GOG 172 or GOG 114 were analyzed separately. Hence, the relationship between IP chemotherapy initiation and time from surgery needs to be studied further.",
keywords = "NRG Oncology, Ovarian cancer, Time interval between surgery and IP chemo",
author = "Garcia-Soto, {Arlene E} and Java, {James J.} and Wilberto Nieves-Neira and Matt Pearson and Cohn, {David E.} and Lele, {Shashikant B.} and Tewari, {Krishnansu S.} and Walker, {Joan L.} and {Alvarez Secord}, Angeles and Armstrong, {Deborah K.} and Copeland, {Larry J.}",
year = "2016",
doi = "10.1016/j.ygyno.2016.10.003",
language = "English (US)",
volume = "143",
pages = "484--489",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study

AU - Garcia-Soto, Arlene E

AU - Java, James J.

AU - Nieves-Neira, Wilberto

AU - Pearson, Matt

AU - Cohn, David E.

AU - Lele, Shashikant B.

AU - Tewari, Krishnansu S.

AU - Walker, Joan L.

AU - Alvarez Secord, Angeles

AU - Armstrong, Deborah K.

AU - Copeland, Larry J.

PY - 2016

Y1 - 2016

N2 - Objectives To determine the relationship of the time from surgery to intraperitoneal (IP) chemotherapy (TSIC) initiation with survival of patients with stage III epithelial ovarian cancer (EOC) patients using ancillary data from cooperative group clinical trials. Methods Data from 420 patients with stage III EOC treated with IP chemotherapy under GOG-0114 and 172 were reviewed. The Cox proportional hazards model was used to evaluate independent prognostic factors and estimate their covariate-adjusted effects on PFS and OS. Results The median TSIC was 62.5 days (interquartile range 28–83). The median TSIC was longer for patients in GOG-0114 vs those in GOG-172 (83 vs 26 days, p < 0.001). TSIC was significantly associated (p = 0.049) with PFS: each 10% increase in TSIC (days) decreases the risk of progression by 3%. TSIC was not significantly associated with OS in this model. In a linear regression model, gross residual disease was significantly associated with shorter TSIC (R2 − 0.141, 95%CI − 0.217, − 0.064, p < 0.001). When only data from GOG-172 were considered, no statistical significant association was found between TSIC and PFS or OS. Conclusions In this ancillary data study, TSIC was not associated with improved OS in patients with stage III epithelial ovarian cancer. TSIC was significantly associated with PFS for the entire cohort, suggesting increase in PFS with longer TSIC. However, this was not found when only data from GOG 172 or GOG 114 were analyzed separately. Hence, the relationship between IP chemotherapy initiation and time from surgery needs to be studied further.

AB - Objectives To determine the relationship of the time from surgery to intraperitoneal (IP) chemotherapy (TSIC) initiation with survival of patients with stage III epithelial ovarian cancer (EOC) patients using ancillary data from cooperative group clinical trials. Methods Data from 420 patients with stage III EOC treated with IP chemotherapy under GOG-0114 and 172 were reviewed. The Cox proportional hazards model was used to evaluate independent prognostic factors and estimate their covariate-adjusted effects on PFS and OS. Results The median TSIC was 62.5 days (interquartile range 28–83). The median TSIC was longer for patients in GOG-0114 vs those in GOG-172 (83 vs 26 days, p < 0.001). TSIC was significantly associated (p = 0.049) with PFS: each 10% increase in TSIC (days) decreases the risk of progression by 3%. TSIC was not significantly associated with OS in this model. In a linear regression model, gross residual disease was significantly associated with shorter TSIC (R2 − 0.141, 95%CI − 0.217, − 0.064, p < 0.001). When only data from GOG-172 were considered, no statistical significant association was found between TSIC and PFS or OS. Conclusions In this ancillary data study, TSIC was not associated with improved OS in patients with stage III epithelial ovarian cancer. TSIC was significantly associated with PFS for the entire cohort, suggesting increase in PFS with longer TSIC. However, this was not found when only data from GOG 172 or GOG 114 were analyzed separately. Hence, the relationship between IP chemotherapy initiation and time from surgery needs to be studied further.

KW - NRG Oncology

KW - Ovarian cancer

KW - Time interval between surgery and IP chemo

UR - http://www.scopus.com/inward/record.url?scp=84992359710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992359710&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2016.10.003

DO - 10.1016/j.ygyno.2016.10.003

M3 - Article

C2 - 27726923

AN - SCOPUS:84992359710

VL - 143

SP - 484

EP - 489

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -